Meeting
2022 ASCO Annual Meeting
Updated efficacy and safety report of a phase I trial of donor-derived CD7 CAR T cells for T-cell acute lymphoblastic leukemia.
Authors
Jing Pan
State Key Laboratory of Experimental Hematology, Department of Hematology, Beijing Boren Hospital, Beijing, China
Jing Pan , Yue Tan , Guoling Wang , Biping Deng , Zhuojun Ling , Weiliang Song , Jiajia Duan , Jinlong Xu , Zelin Wang , Xiaoming Feng , Alex H. Chang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
ChiCTR2000034762
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7023)
DOI
10.1200/JCO.2022.40.16_suppl.7023
Abstract #
7023
Poster Bd #
254
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase I study of donor-derived CD5 CAR T cells in patients with relapsed or refractory T-cell acute lymphoblastic leukemia.
First Author: Jing Pan
Poster
2016 ASCO Annual Meeting
Determination of the effect of target site density on the efficacy of CD22 chimeric antigen receptor t-cell therapy to treat acute lymphoblastic leukemia.
First Author: Sang Nguyen
First Author: Marco L. Davila
Poster
2020 ASCO Virtual Scientific Program
Efficacy of SCRI-CAR19x22 T cell product in B-ALL and persistence of anti-CD22 activity.
First Author: Rebecca Alice Gardner